Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Erkelenz – page 17

1 570 clinical trials in Erkelenz, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Erkelenz at a glance
1 570
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 570 trials in Erkelenz

Open in trial search

Evaluating the efficacy of pirtobrutinib and epcoritamab in patients with untreated Richter transformation of chronic lymphocytic leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:University Of Cologne

Effect of sodium hydrogen carbonate on kidney health in critically ill patients with metabolic acidosis and acute kidney injury

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium acetate
  • Sponsor:Universitaet Muenster

Breast cancer+4

Recruiting

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elacestrant
  • Sponsor:WSG Women's Cancer Study Group GmbH

A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:Liquidia Technologies Inc.

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A study to evaluate the safety and effectiveness of urokinase, catalytic domain, fused with a single-chain antibody against von Willebrand factor in patients with immune-mediated thrombotic thrombocytopenic purpura.

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Urokinase, catalytic domain, fused with a single-chain antibody against VON willebrand factor
  • Sponsor:TargED Biopharmaceuticals B.V.

A study to evaluate the effectiveness of R2R01 in preventing acute kidney injury in patients at high risk following heart surgery.

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:R2R01
  • Sponsor:River 2 Renal Corp.

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.

Short stature+1

Recruiting

Study of Lonapegsomatrin and Somatropin in Children and Adolescents with Short Stature or Growth Failure due to Turner Syndrome, SHOX Deficiency, SGA, or Idiopathic Short Stature

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Lonapegsomatropin
  • Sponsor:Ascendis Pharma Endocrinology Division A/S

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Olema Pharmaceuticals Inc.

A study to evaluate the effectiveness of AZD5148 in preventing the recurrence of Clostridioides difficile infection in adults.

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5148
  • Sponsor:AstraZeneca AB

Study of ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Kura Oncology Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Erkelenz

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on triple-negative breast cancer evaluating the effectiveness of combining immunotherapy with traditional chemotherapy treatments. Studies aim to improve patient outcomes through personalized therapeutic approaches.

  • Triple-Negative Breast Cancer Treatment
  • Immunotherapy Integration
  • Event-Free Survival Assessment

Research explores novel combination therapies to enhance treatment efficacy.

02 Hormone Receptor Research

Studies examining personalized treatment strategies for HR+/HER2- breast cancer patients, comparing endocrine therapy combinations with standard chemotherapy approaches. Focus on long-term survival outcomes.

  • Endocrine Therapy Enhancement
  • Disease-Free Survival Analysis
  • Personalized Treatment Protocols

Investigation of targeted therapies to improve treatment effectiveness.

03 Advanced Treatment Studies

Research evaluating novel therapeutic approaches for HER2-negative breast cancer patients, particularly those at high risk of relapse after standard treatments. Focus on comparing innovative targeted therapies with conventional approaches.

  • High-Risk Patient Treatment
  • Relapse Prevention Strategies
  • Comparative Treatment Efficacy

Development of targeted solutions for challenging breast cancer cases.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.